Navigation Links
KV Pharmaceutical Company Announces NYSE Listing Extension
Date:12/28/2007

s", "commit", "intend", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements. The Company can give no assurances that its outstanding SEC filings discussed above will be made by February 15, 2008, that it will not request the NYSE to agree to further extend the listing of the Company's securities beyond February 15, 2008, or, if requested, that the NYSE will grant a further listing extension.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials; (8) the regulatory envir
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ique to combat cancer, study says, , ,...archers have discovered that some cancer cells use...ight lead to new treatments that starve and kill t...ells in the body need to produce energy. They do t...uires oxygen. Compared with normal cells, tumor ce...
(Date:11/21/2008)...wswire/ -- New research at West Virginia Universi...acco product aimed at young adults is catching on....Camel Snus - touted as a socially acceptable way t...evels of nicotine. , , "Camel Snus contains...id Bruce Adkins of the state Division of Tobacco P...
(Date:11/21/2008)...tect Investment And Restore Shareholder Value , ... -- Dr. Stephen Joffe, Craig Joffe, and Alan Bucke...ith the U.S. Securities and Exchange Commission. ...hip of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV )...ion correction centers in 33 states in the United ...
(Date:11/21/2008)...al membership of the Medical,Advertising Hall of ...r Annual,Awards Dinner to be held February 10, 20...hievement Award will also be given. , The 2... Fame are: , Ronald Pantello, who began his adv...r & Hennessey. In 1980 he left Sudler & He...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3
...ates that nearly 30,000 men will die from prostate...e for these patients: // The combination of androg...ation therapy improves survival rates. AST inhibit...ormone. Researchers say that combining three years...
... long, continuous workouts to be beneficial. Howev...be a more effective way // to lower fat in the blo...rcises affect triglyceride levels. Triglycerides a...odstream. Study participants were followed for thr...
...ternal defibrillators in public places can improve...rt attack.// Researchers randomly placed AEDs -- ...al during a heart attack -- in nearly 1,000 shoppi... public places in 24 communities in North America....
...ppositional Defiant Disorder ( ODD ) may be to bla...died children // between ages 6 and 17 who were di...re given a questionnaire and were further evaluate...e study show there is a relationship between pedia...
Other Medicine News:
(Date:11/20/2008)...RK, Nov. 20 Clinical data from a p...th Annual Veith Symposium shows DVT,treatment wit...acchus,Vascular, Inc. (Santa Clara, CA) successfu...about 20 minutes. , This technique, called ...,blood flow more quickly and safely than current ...
(Date:11/19/2008)... , Study did not achieve statistical significan...irstCall/ -- Pharmos Corporation (Nasdaq: PARS )...l trial of its topical NanoEmulsion (NE) drug deli...hanolamine. , , The multi-center, randomize...ted the safety and efficacy of the Company,s 3% Di...
(Date:11/18/2008)..., November 19 NeuroDisco...vice provider and drug development Company,and S...: 4565), a leading,international biopharmaceutica...presenting further pivotal pre-clinical efficacy d...is a potential therapy for neuropathic pain and ha...
(Date:11/18/2008)...ized study will enroll newly diagnosed, elderly AM...Newswire/ -- Celator Pharmaceuticals today announc...ndomized Phase 2 clinical study of CPX-351 (Cytara...with newly diagnosed acute myeloid leukemia (AML).... Feldman, MD at the Weill Medical College of Corn...
Breaking Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Watching Violent TV at Pre School Age Linked to Aggression in Young Boys 5462 1Watching Violent TV at Pre School Age Linked to Aggression in Young Boys 5462 2Watching Violent TV at Pre School Age Linked to Aggression in Young Boys 5462 3Watching Violent TV at Pre School Age Linked to Aggression in Young Boys 5462 4Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 5459 1Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 5459 2Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 5459 3Hundreds of Benefit Fund Trustees Question Viability of Rite Aid Pharmacy Benefit Management Company 5459 4Rare cancer causing syndrome found for the first time in Singapore 1095 1Rare cancer causing syndrome found for the first time in Singapore 1095 2Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientifi 5456 1Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientifi 5456 2
...(BUSINESS WIRE)--Jun 21, 2007 - Nymox,Pharmaceutic...,detailed results from the Company,s recently comp...rplasia (BPH) will be presented at,a series of upc...r,at the South Central American Urological Associa...t podium presentations will be,given by leading cl...
...PRNewswire/ -- , What and When , Data from the PRO...ne HCl) will be presented in poster format at the ...Association in,Chicago: , , -- Hospitalizations... diabetes patients treated with pioglitazone ...r 0553-P presented on Saturday, June 23, from 12:3...
Other Medicine Technology:Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 3
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option.
300XL System, English (U.K. cord), 100-240 VAC.
Micro-mini fiber optic light.
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light.
Medicine Products: